Glaukos Growth Broadens as Epioxa Adds a Second Engine
Glaukos is expanding beyond a single-product business, with its iDose TR glaucoma treatment and newly launched Epioxa supporting growth. Second-quarter net sales rose 50% year over year to $185.6 million. Non-GAAP gross margin reached 85%, and the company reported a breakeven P&L.
Management raised its 2026 net sales guidance to $680 million–$700 million, including expected iDose TR sales of $275 million–$280 million and growth of more than 20% in its corneal health business. Glaukos also has a second growth driver in Epioxa, whose commercial launch and insurance coverage could help diversify revenue.
A key risk is whether five Medicare contractors finalize proposed coverage limits for iDose TR. The restrictions could weigh on adoption, but the article presents the risk as material rather than certain to derail growth. For Glaukos, the balance between Medicare coverage and Epioxa’s launch will be important to future sales and investor expectations.
Neutral
The article concerns Glaukos, an ophthalmic pharmaceutical company, and does not report a cryptocurrency, blockchain project or digital-asset market catalyst. Its sales growth, updated guidance and Medicare coverage risks therefore have no clear direct effect on crypto prices, trading volumes or market stability. Any connection would be indirect: broader changes in investor risk appetite can sometimes affect both equities and crypto, but the article provides no evidence of such a market-wide shift. In the short term, crypto traders are unlikely to react materially. Over the longer term, the company-specific developments may matter to Glaukos investors, but they do not change the fundamentals of major crypto assets. A neutral crypto-market assessment is therefore appropriate.